ANI Pharmaceuticals, Inc. — Filing Summary
Filing identity: The supplied filing is BioSante Pharmaceuticals, Inc.’s Form 10-K, not an ANI Pharmaceuticals standalone 10-K. It reports the fiscal year ended December 31, 2012, and was signed February 28, 2013. The proposed combination with ANI was pending at the filing date.
Business context and reporting period
BioSante was a specialty pharmaceutical company focused on female sexual health, menopause, contraception and male hypogonadism. Its portfolio included LibiGel and The Pill-Plus in development, and FDA-approved Elestrin and a male testosterone gel licensed to commercial partners. BioSante had no commercial sales force or manufacturing facilities and relied on licensees and third parties.
On October 3, 2012, BioSante agreed to merge with privately held ANI. Subject to approvals and other conditions, ANI stockholders were expected to own about 53% and BioSante stockholders about 47% of the combined company, assuming BioSante net cash of $18 million. ANI’s stockholder meeting and BioSante’s meeting were scheduled for March 15, 2013; closing was not assured.
Financial results and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $2.30 million | $0.44 million |
| Research and development expense | $16.89 million | $44.18 million |
| General and administrative expense | $8.23 million | $6.98 million |
| Total expenses | $25.47 million | $51.36 million |
| Net loss | $27.72 million | $51.61 million |
| Basic and diluted loss per share | $1.27 | $3.15 |
| Net cash used in operating activities | $25.28 million | $47.87 million |
| Cash and cash equivalents at year-end | $34.79 million | $57.23 million |
- Fourth-quarter 2012 revenue was $1.97 million, versus $114,373 in fourth-quarter 2011. Fourth-quarter net loss was $3.99 million, versus $6.65 million; loss per share was $0.16 versus $0.36.
- Cash and cash equivalents fell $22.43 million during 2012. Financing provided $3.47 million, mainly from an August registered offering; investing used $0.62 million.
- At December 31, 2012, total assets were $38.77 million, current liabilities were $10.59 million, and stockholders’ equity was $28.18 million. The filing reported no credit facilities.
- $8.28 million principal amount of 3.125% convertible senior notes remained outstanding, due May 1, 2013; the recorded fair value was $7.88 million. Contractual obligations due within one year totaled approximately $8.96 million, including the notes, interest and lease/license commitments.
- BioSante reported an accumulated deficit of $244.96 million and said it expected continuing losses. It reported no meaningful product gross-margin trend; the filing does not provide a clear standalone gross-margin measure.
Material changes versus prior period
- Revenue rose to $2.30 million from $0.44 million, primarily due to $1.75 million of Teva payments under an October 2012 agreement amendment. Elestrin royalties were $0.55 million and were offset by royalties payable to Antares.
- R&D expense declined 62%, mainly because the two prior LibiGel efficacy trials ended in 2011 and the safety study concluded in September 2012. G&A expense increased 18%, primarily due to professional and transaction-related costs, including the proposed merger.
- Net loss narrowed by $23.89 million, although the 2012 result included a $4.33 million convertible-note fair-value expense, including a noncash adjustment associated with exchanges of $12.5 million principal for 3.65 million shares. BioSante also issued $3.27 million net proceeds of stock and warrants during 2012.
- BioSante reduced headcount from 23 employees at December 31, 2012 to 12 at February 28, 2013. It wrote down its gel-filling equipment by $929,431 to zero.
- The common stock’s reported quarterly trading range fell from $2.28–$16.56 in Q4 2011 to $1.08–$1.97 in Q4 2012. Share and per-share data reflect a one-for-six reverse split effective June 1, 2012.
Outlook, risks, contingencies and unusual items
- LibiGel: The two prior Phase III efficacy trials failed to meet co-primary and secondary endpoints; the filing attributed the result to a larger-than-expected placebo response. BioSante planned to develop protocols for two new Phase III trials and seek an FDA Special Protocol Assessment. Estimated cost was $30–$36 million over about 18 months, requiring additional financing if pursued. The cardiovascular and breast-cancer safety study was ended after the monitoring committee recommended continuing it without modifications; BioSante said it believed the accumulated exposure provided adequate safety data, while remaining blinded to treatment allocation.
- Management outlook: BioSante estimated 2013 R&D expense of about $2.5 million, assuming no further LibiGel development and completion of the merger; the estimate excluded post-merger combined-company R&D. If the merger did not close, BioSante said it would reassess strategic alternatives. It estimated existing year-end cash could support three to five years of operations only if it did not pursue the new LibiGel trials and did not enter another strategic transaction.
- Merger conditions and dilution: Closing required stockholder approvals, Nasdaq listing approval, tax opinions and customary conditions. ANI could decline to close if BioSante’s defined net cash was below $17 million. The exchange ratio could change with net cash, and ANI holders’ ownership could not fall below 50.1%. A reverse split and company name change were also proposed.
- Debt maturity: The notes were due May 1, 2013. BioSante believed it could pay them but warned that it might not have sufficient funds; certain events could accelerate repayment. Liquidity estimates were conditional, and no borrowing facility was available.
- Litigation: A securities class action and shareholder derivative suits relating to disclosures about LibiGel were pending. BioSante disputed the claims; outcomes and potential losses were not estimable, and no litigation liability was accrued at year-end.
- Other items: In January 2013, BioSante sold its GVAX cancer-vaccine assets to Aduro for $1 million upfront plus potential future payments. It also funded a $2.3 million rabbi trust for potential executive severance. The proposed merger carried estimated combined transaction costs of about $3.1 million; BioSante could owe up to $1 million termination fee and reimburse ANI expenses up to $500,000 in specified circumstances.
- BioSante reported effective disclosure controls and internal control over financial reporting. The auditor gave unqualified opinions on the financial statements and internal controls.
Most important facts for investors to verify
- Whether the merger closed, the final net-cash calculation, exchange ratio, ownership split, Nasdaq listing and reverse-split terms.
- Cash available after the merger, the treatment and repayment of the May 2013 convertible notes, and actual severance and transaction costs.
- Whether BioSante pursued the proposed LibiGel trials, secured an FDA SPA and obtained funding; assess the failed prior efficacy endpoints against the safety-study results.
- Whether Teva launched the approved male testosterone gel, its AB-rated status, and any resulting milestone or royalty receipts.
- Subsequent developments in the LibiGel-related litigation and any resulting financial exposure.
- Actual post-merger operating performance and cash flows: the filing’s liquidity and expense projections were conditional and are not assurances.